Cognetivity Neurosciences Ltd.
CGNSF · OTC
1/31/2023 | 1/31/2022 | 1/31/2021 | 1/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.01 | 0.40 | 0.08 |
| FCF Yield | -28.97% | -10.03% | -5.99% | -21.35% |
| EV / EBITDA | -3.10 | -2.53 | -13.56 | -3.29 |
| Quality | ||||
| ROIC | 97.17% | 577.92% | -203.65% | -5,889.85% |
| Gross Margin | -4,694.86% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.24 | 1.02 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -81.38% | -65.00% | -6.94% | 46.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 0.01 | 0.44 | 0.10 |
| Interest Coverage | -6.12 | -215.30 | -38.09 | -46.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,628.36 | -12,684.56 | -20,319.19 | -24,710.88 |